JP6629216B2 - 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 - Google Patents

上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 Download PDF

Info

Publication number
JP6629216B2
JP6629216B2 JP2016551030A JP2016551030A JP6629216B2 JP 6629216 B2 JP6629216 B2 JP 6629216B2 JP 2016551030 A JP2016551030 A JP 2016551030A JP 2016551030 A JP2016551030 A JP 2016551030A JP 6629216 B2 JP6629216 B2 JP 6629216B2
Authority
JP
Japan
Prior art keywords
composition
acid
pea starch
microparticles
microparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016551030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535094A5 (enExample
JP2016535094A (ja
Inventor
マリオ ルドウィック キリンジェレス，ディディラー
マリオ ルドウィック キリンジェレス，ディディラー
ディジック，アレックス アンリ バン
ディジック，アレックス アンリ バン
メンシチ，ユルゲン
アルバート マルコム ブルース
アルバート マルコム ブルース
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2016535094A publication Critical patent/JP2016535094A/ja
Publication of JP2016535094A5 publication Critical patent/JP2016535094A5/ja
Application granted granted Critical
Publication of JP6629216B2 publication Critical patent/JP6629216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016551030A 2013-11-06 2014-11-05 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 Expired - Fee Related JP6629216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191742.9 2013-11-06
EP13191742 2013-11-06
PCT/EP2014/073762 WO2015067632A1 (en) 2013-11-06 2014-11-05 Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Publications (3)

Publication Number Publication Date
JP2016535094A JP2016535094A (ja) 2016-11-10
JP2016535094A5 JP2016535094A5 (enExample) 2017-12-14
JP6629216B2 true JP6629216B2 (ja) 2020-01-15

Family

ID=49517426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551030A Expired - Fee Related JP6629216B2 (ja) 2013-11-06 2014-11-05 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤

Country Status (11)

Country Link
US (1) US20160271165A1 (enExample)
EP (1) EP3065714B1 (enExample)
JP (1) JP6629216B2 (enExample)
KR (1) KR20160072140A (enExample)
CN (1) CN105939709A (enExample)
AU (1) AU2014345667A1 (enExample)
CA (1) CA2929142A1 (enExample)
IL (1) IL245412A0 (enExample)
MX (1) MX2016005883A (enExample)
RU (1) RU2016117398A (enExample)
WO (1) WO2015067632A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515530A (ja) * 2015-05-11 2018-06-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 上気道感染症の予防および／または治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））のエンドウマメデンプン製剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866230C (en) 2012-05-03 2020-08-18 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
CA3005492C (en) 2015-11-17 2023-01-10 Bioncotech Therapeutics Sl Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN110177545A (zh) 2016-11-16 2019-08-27 爱尔兰詹森科学公司 用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂
CN115998757A (zh) 2017-05-17 2023-04-25 亮点医疗有限责任公司 包含具有双链多核糖核苷酸和聚乙烯亚胺的复合物的粒子的新型药物组合物
KR102123489B1 (ko) 2020-03-13 2020-06-16 주식회사 휴먼셀바이오 자연살해세포 배양액 조성물 및 이를 이용한 자연살해세포 배양방법
WO2021213946A1 (en) 2020-04-19 2021-10-28 Englmeier Ludwig Prophylaxis and treatment of coronavirus infection
CN118680868A (zh) * 2023-03-24 2024-09-24 清华大学 一种核酸药物递送系统及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
CN101229378A (zh) * 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
CN101491503A (zh) * 2008-12-17 2009-07-29 天津瑞普生物技术股份有限公司 一种用于宠物的聚肌胞滴丸及其制备方法
CN101757018A (zh) * 2008-12-24 2010-06-30 天津瑞普生物技术股份有限公司 一种用于畜禽的聚肌胞干粉及其制备方法
CN102488703A (zh) * 2011-12-15 2012-06-13 天津济命生生物科技有限公司 一种聚肌胞制剂的制备方法和抗肿瘤的用途
CA2866230C (en) * 2012-05-03 2020-08-18 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515530A (ja) * 2015-05-11 2018-06-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 上気道感染症の予防および／または治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））のエンドウマメデンプン製剤

Also Published As

Publication number Publication date
RU2016117398A3 (enExample) 2018-08-22
AU2014345667A1 (en) 2016-05-19
EP3065714A1 (en) 2016-09-14
CN105939709A (zh) 2016-09-14
KR20160072140A (ko) 2016-06-22
IL245412A0 (en) 2016-06-30
RU2016117398A (ru) 2017-12-11
JP2016535094A (ja) 2016-11-10
MX2016005883A (es) 2016-08-17
US20160271165A1 (en) 2016-09-22
CA2929142A1 (en) 2015-05-14
WO2015067632A1 (en) 2015-05-14
EP3065714B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
JP6629216B2 (ja) 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸（ポリ（ｉ：ｃ））製剤
US10485816B2 (en) Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
US20180353533A1 (en) Polyinosinic-polycytidylic acid (poly (i:c)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections
US20200060972A1 (en) Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections
HK1228749A1 (en) Polyinosinic-polycytidylic acid (poly (i:c) formulations for the treatment of upper respiratory tract infections
HK1203390B (zh) 用於治疗上呼吸道感染的聚肌苷酸-聚胞苷酸(聚(i:c))配制品
EP2385834B1 (de) Verwendung von deuteriumoxid zur behandlung virus-basierter erkrankungen des respirationstraktes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191204

R150 Certificate of patent or registration of utility model

Ref document number: 6629216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees